SMDAM
NKTR icon

Sumitomo Mitsui DS Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Sumitomo Mitsui DS Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-589
Closed -$314K – 719
2019
Q2 		$314K Sell
589
-165
-22% -$82.7K 0.01% 636
2019
Q1 		$379K Buy
754
+9
+1% +$5.33K 0.01% 725
2018
Q4 		$367K Hold
745
– – 0.01% 695
2018
Q3 		$681K Hold
745
– – 0.01% 627
2018
Q2 		$546K Buy
+745
New +$859K 0.01% 668

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management's NKTR Position: Q3 2019 in Review

Sumitomo Mitsui DS Asset Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 589 shares — an estimated $314K sold.

Sumitomo Mitsui DS Asset Management first reported a position in NKTR in Q2 2018 and held it in 5 quarters. The position peaked at $681K in Q3 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Sumitomo Mitsui DS Asset Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Sumitomo Mitsui DS Asset Management sold 589 Nektar Therapeutics shares in Q3 2019, an estimated $314K.
  • Sumitomo Mitsui DS Asset Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 5 quarters.
  • Sumitomo Mitsui DS Asset Management's Nektar Therapeutics position peaked at $681K in Q3 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.